{"id":"https://genegraph.clinicalgenome.org/r/55bd0b0f-fb68-4b02-9a58-de329fca71ccv1.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between FOXRED1 and Leigh syndrome spectrum was evaluated using the ClinGen Clinical Validity Framework as of October 14, 2019. Variants in FOXRED1  were first reported in humans with Leigh syndrome spectrum as early as 2010 (PMID: 20818383). Four unique variants predicted to cause a loss of or reduced function of the protein have been reported in ClinVar, suggesting loss of function is the mechanism of disease for this gene. Evidence supporting this gene-disease relationship includes case-level data and experimental data. Two probands with confirmed FOXRED1  mutations demonstrating a Leigh syndrome spectrum phenotype have been reported in 2 publications (PMIDs: 26022995, 20818383) to reach a case-level evidence score of 4. This gene-disease association is further supported by FOXRED1â€™s protein interaction and shared function with other genes associated with Leigh syndrome spectrum, mitochondrial alterations in patient cell lines, and a FOXRED1 mouse model exhibiting a neuropathological and behavioral phenotype, reaching an experimental score of 5 pts. In summary, there is moderate evidence to support the relationship between FOXRED1 and autosomal recessive Leigh syndrome spectrum. This classification was approved by the NICHD U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on October 14, 2019 (SOP Version 7).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/55bd0b0f-fb68-4b02-9a58-de329fca71cc","GCISnapshot":"https://genegraph.clinicalgenome.org/r/c74ba0cb-ccef-4a19-9fef-ef9996f72290","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/c74ba0cb-ccef-4a19-9fef-ef9996f72290_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2019-10-16T14:34:53.574Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/c74ba0cb-ccef-4a19-9fef-ef9996f72290_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c74ba0cb-ccef-4a19-9fef-ef9996f72290_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c74ba0cb-ccef-4a19-9fef-ef9996f72290_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/afa5bbaf-45b2-49a3-9023-278d6006a645","type":"EvidenceLine","dc:description":"Utilized model scoring system developed for Leigh syndrome experimental evidence. (1/3 pts for neuropathology evidence, and 0.5/1 pts for neurocognitive behavioral differences)","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18eeee3f-2128-47a1-847e-1b555544e1ce","type":"Finding","dc:description":"Results showed neurobehavioral changes in the injected mice along with parallel degeneration in corpus striatum and sparing of the substantia nigra similar to what happen in Leigh syndrome cases","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30392038","rdfs:label":"FOXRED1 mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c74ba0cb-ccef-4a19-9fef-ef9996f72290_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76e7b174-8557-4216-b217-3b4cf1f086f7","type":"EvidenceLine","dc:description":"This is a second patient cell culture model with FOXRED1 mutations demonstrating evidence of mitochondrial dysfunction (Awarded 0.5 pts)","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/342259d9-74fb-4985-82cb-a1cc7b7e9444","type":"FunctionalAlteration","dc:description":"Cells demonstrated decreased complex I activity and assembly. The enzymatic activity of complex I (expressed as complex I / complex II ratio) was 18% of mean normal activity, confirming complex I deficiency. Blue-Native Polyacrylamide Gel Electrophoresis (BN-PAGE) analysis showed a significant decrease in CI/CII assembly level in patient's fibroblast (8% of mean normal control value)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31065540","rdfs:label":"Fibroblast Studies_Apatean"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/69e8b16c-167e-48b9-a516-dab1b8c27db2","type":"EvidenceLine","dc:description":"one patient cell culture model with disrupted gene function showing mitochondrial dysfunction in a non-neuronal cell type (Awarded 1 pt)","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f77cee2c-4fef-437b-809d-df6dffa3eacc","type":"FunctionalAlteration","dc:description":"Patient fibroblasts demonstrated reduced complex I activity, decreased levels of fully assembled complex I, the accumulation of complex I subcomplexes, and, unexpectedly, decreased levels of fully assembled complex II. FOXRED1 was decreased in the patient myoblast line compared to controls. Both the assembly defects and FOXRED1 levels were rescued by retroviral expression of wild-type FOXRED1.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27215383","rdfs:label":"FOXRED1_fibroblast studies"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c74ba0cb-ccef-4a19-9fef-ef9996f72290_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/13492146-6e94-45b4-88e2-7f4e35845a24","type":"EvidenceLine","dc:description":"The FOXRED1 encoded protein shares a biochemical relationship or function with 6-10 gene products whose dysfunction is known to cause Leigh syndrome (Awarded 1.5 pt)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ac9cc348-3f48-4516-8b64-1c1fe96b37b7","type":"Finding","dc:description":"FOXRED1 is a nuclear encoded complex 1 assembly unit, involved in mid-late stages of complex I assembly. (PMID:25678554) According to Leigh map, at least six other complex I assembly units have been implicated in causing Leigh Syndrome (NDUFAF2, NDUFAF4, NDUFAF5, NDUFAF6, NUBPL, and C17ORF89) (Rahman 2017 PMID: 27977873). Therefore, the function of FOXRED1 is shared with other known genes in the disease of interest.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25678554","rdfs:label":"FOXRED1 Complex I assembly unit","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/8f308d89-0dc0-4e8b-8a82-94696d53083b","type":"EvidenceLine","dc:description":"The FOXRED1 encoded protein interacts with 2-5 gene products whose dysfunction is known to cause Leigh syndrome (Awarded 1 pt)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db293ac7-d481-4857-8966-ef593199c54e","type":"Finding","dc:description":"FOXRED1 co-immunoprecipitated with a number of complex I subunits including NDUFB10, NDUFS5, NDUFA10, NDUFA8, NDUFS3 and NDUFA5. As per Leigh Map, NDUFA10 and NDUFS3 have been implicated in causing Leigh syndrome (Rahman 2017 PMID: 27977873). Therefore, FOXRED1 physically interacts with other known genes in the disease of interest.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25678554","rdfs:label":"FOXRED1 immunoprecipitation","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5},{"id":"https://genegraph.clinicalgenome.org/r/c74ba0cb-ccef-4a19-9fef-ef9996f72290_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a1889442-d1cb-4241-b940-544190524fb5_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A score of 1.5 pts was awarded to this case as complementation studies in patient fibroblasts with wild type FOXRED1 restored complex I activity.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ceea7ac7-0ea2-4b39-9ea6-8a23188ee169","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26022995","rdfs:label":"Fassone Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"Eleven genes were sequenced by cycle sequencing (Big Dye) and analysis on MegaBACE","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Brain MRI was consistent with Leigh like Syndrome. At 8 mos, Brain MRI revealed delayed myelination, ventricular dilation and abnormal signal in the thalami and basal ganglia","phenotypes":["obo:HP_0003128","obo:HP_0001263"],"previousTesting":true,"previousTestingDescription":"SNP array testing was normal. Homozygosity mapping detected 5 candidate regions unique to proband and not detected in unaffected siblings. Of the 337 genes located in these regions, 11 genes associated with mitochondria were prioritized for sequencing.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a1889442-d1cb-4241-b940-544190524fb5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26022995","allele":{"id":"https://genegraph.clinicalgenome.org/r/3e1691aa-45c3-412e-98f8-c7aa92a487b0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017547.4(FOXRED1):c.1054C>T (p.Arg352Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/31048"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9fd5d048-2bd2-4f90-8af7-50757ef509ee_proband_score_evidence_line","type":"EvidenceLine","dc:description":"2.5 pts were awarded as the c.694C>T (p.Q232X) mutation is a nonsense mutation and complementation studies in patient fibroblasts with wild type FOXRED1 were able to rescue the complex 1 defect.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ce59f5a-0f95-4af9-a9ee-88870bb92ee6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20818383","rdfs:label":"Patient DT22","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","phenotypeFreeText":"Brain MRI consistent with Leigh syndrome. MRI at 6 years of age showed areas of decreased attenuation in the putamen bilaterally and significant cerebellar atrophy, consistent with a diagnosis of Leigh syndrome. Fibroblasts from this patient exhibited a a CI defect, with only 9% residual CI activity when assayed by spectrophometric enzyme assay","phenotypes":["obo:HP_0003128","obo:HP_0001263"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/9fd5d048-2bd2-4f90-8af7-50757ef509ee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20818383","allele":[{"id":"https://genegraph.clinicalgenome.org/r/04c4fbc4-5fcf-436d-bf88-cd98a8ab4f65","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017547.4(FOXRED1):c.1289A>G (p.Asn430Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/6"}},{"id":"https://genegraph.clinicalgenome.org/r/20614174-6861-4845-8a62-95b1676e0d05","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017547.4(FOXRED1):c.694C>T (p.Gln232Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Moderate","sequence":410,"specifiedBy":"GeneValidityCriteria6","strengthScore":9,"subject":{"id":"https://genegraph.clinicalgenome.org/r/cmKZPg3Typo","type":"GeneValidityProposition","disease":"obo:MONDO_0009723","gene":"hgnc:26927","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_c74ba0cb-ccef-4a19-9fef-ef9996f72290-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}